Sandoz, a specialist in generic and biosimilar medicines, has revealed plans for an additional investment of €50m to support the increased European manufacturing capabilities for finished dosage form ...

Nearly 100 years ago the world of medicine was revolutionised by the discovery of penicillin and the dawn of the ‘antibiotic era’. These medicines have become the backbone of modern medicine ...

Sandoz' parent Novartis exited novel antibiotics R&D four years ago, joining an exodus from the sector by big pharma companies that has raised fears of increasing numbers of infections that will ...

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help ...

Sandoz Group. MEDIA RELEASE. EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe ...

Sandoz, whose first day of trading is scheduled for Oct. 4, has previously said its development pipeline has 25 future biosimilars, cheaper versions of off-patent biologic drugs made from modified ...

EUR 50 m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000 m 2 means ...

Basel, March 21, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today opened a new production facility in Kundl, Austria, to serve more patients with affordable life ...